Breast cancer is one of the most common diseases in women and almost an eighth of the women population is suffering from breast cancer. Currently, there are several methods to diagnose and treat breast cancer, including genetic screening. However, this is not an end-all cure as the largest concern after an adenomammectomy is metastasis to other tissues.
A recent study, describes a new and simple method to assess the risk of metastasis and identified 21 DNA hypermethylated hotspots, in cell-free, circulating DNA, that are associated with breast cancer metastasis. These 21 sites together serve as a biomarker, which give insight into the status of the tumor tissue, as well as to the health of other organs. The group hopes that the methylation signature of the 21 sites can be used to indicate micrometastatic disease in the pre-macrometastatic setting and ultimately may identify patients at a high-risk of breast cancer recurrence, providing justification for continued treatment.
The group performed whole-genome bisulfite sequencing on cell-free, circulating DNA, found in the blood of forty patients with breast cancer metastasis and compared it to forty healthy people and forty patients with no recurrence. They identified 21 sites that were differentially methylated between the samples. Compared to healthy people and patients with no recurrence, samples from patients with a higher risk of metastasis were hypermeythlayted at the identified hotspots.
By identifying high risk individuals early on, doctors can offer treatment options to fight reoccurrence and metastasis before it’s actually happened. Researchers aim to provide a valuable tool in the fight against breast cancer.